Biotech Values

[mcbio]

As far as the Syk inhibitors go, they're behind RIGL as that is what RIGL's lead drug (R788) targets. It's in Phase II for both RA and various lymphomas. Again, the main questions with the drug seem to pertain to safety, not efficacy, and those questions still remain for me after listening to the conference call earlier today. They indicated they expect to have a partner for the drug by end of 1Q 09.